Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

New Results From MediSafe Project's Mobile Technol

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
Posted On: 07/15/2013 9:16:20 AM
Avatar
Posted By: News Desk 2018
New Results From MediSafe Project's Mobile Technology Show High Adherence Rates for Type 2 Diabetes Medication

HAIFA, Israel, July 15, 2013 (GLOBE NEWSWIRE) -- MediSafe Project , ( www.medisafeproject.com ) the first-ever cloud-synced mobile medication reminder solution helping families prevent emergencies caused by over- or under-dosing medications, announced results that show high self-reported medication adherence rates for patients with Type 2 Diabetes. MediSafe Project reviewed medication adherence for its Type 2 Diabetic users, finding compliance rates are at least 26% higher with the mobile technology than general medication adherence rates for long-term therapies, reported as 50% by the World Health Organization .

"Diabetes is a growing disease that has to be controlled throughout a person's entire life. With MediSafe Project, Diabetic patients can better control their condition, improve health outcomes and help provide peace of mind. When dealing with a chronic disease, convenience and routine are imperative. I'm proud to offer a technological solution that provides both," said MediSafe Project CEO, Omri "Bob" Shor.

MediSafe Project analyzed self-reported adherence rates of the most common Type 2 Diabetes medications, proving the use of the mobile pillbox solution dramatically helps patients remember to take their medication on time, and correctly.

Medications reviewed:

  • Glucophage – 79% adherence
  • Januvia – 82% adherence
  • Kombiglyze – 76% adherence
  • Metformin – 78% adherence
  • Onglyza – 77% adherence
  • Sitaglipitin – 80% adherence

Type 2 is the most common type of Diabetes in the country, where the body suffers from insulin resistance. The disease can be treated through lifestyle choices, but more often patients rely on oral medication to control the lifelong chronic illness. It is vital that Type 2 Diabetics follow a plan to manage their condition to help reduce the chances of forgetting to take medication which could lead to ER visits or even be fatal.

"Diabetes can be a debilitating disease if it's not treated properly, and medication adherence plays an important role in managing the chronic condition," said Itamar Raz, M.D., President of the Israel Diabetes Association. "Technology is changing the way people live with diseases by alleviating barriers so patients can live more fulfilling lives. It's solutions such as MediSafe Project that can make a profound impact on adherence, which is a leading issue with Type 2 Diabetics."

The innovative solution not only reminds users when it's time to take their medication, but also uses families', friends' and caretakers' intervention instincts to send alerts when a loved one misses a dose. Patients can receive alerts through the mobile application, which is available in Google Play and iTunes App Store . MediSafe Project is the top rated mobile app in the medication adherence space. The solution also provides the Prescription Page ( doctors.medisafeproject.com ), a method for doctors to prescribe the top-rated pillbox solution to patients, supporting the new patient-centered care model that's being adopted by many PCPs, specialists, hospitals and other health care organizations.

About MediSafe Project

MediSafe Project is the first cloud-synced mobile app helping families prevent emergencies caused by over- or under-dosing medications. In addition to reminding users when it's time to take their medication, MediSafe Project sends alerts to selected family members, friends and caretakers when a loved one misses a dose. Aggregated patient behavior data, physician trends and other market aspects are available to help pharmaceutical companies better understand how people receive and take their medications. Download the MediSafe application from the Google Play and iTunes App Store .  For more information, visit www.MediSafeProject.com .

Jade Trombetta, The Cline Group, 215-313-5002



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us